Mind Medicine (MindMed) Inc
F:MMQ

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
F:MMQ
Watchlist
Price: 6.785 EUR 1.8% Market Closed
Market Cap: 487.7m EUR
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
F:MMQ
Interest Income Expense
$7.4m
CAGR 3-Years
245%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$745m
CAGR 3-Years
19%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$859m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$426.9m
CAGR 3-Years
-100%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
487.7m EUR
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

MMQ Intrinsic Value
2.177 EUR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Interest Income Expense?
Interest Income Expense
7.4m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Interest Income Expense amounts to 7.4m USD.

What is Mind Medicine (MindMed) Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
245%

Over the last year, the Interest Income Expense growth was 58%. The average annual Interest Income Expense growth rates for Mind Medicine (MindMed) Inc have been 245% over the past three years .

Back to Top